Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Mark B. Pepys(University College London), Philip N. Hawkins(The Royal Free Hospital), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Roger D. Norcross(Roche (Switzerland)), Graham W. Taylor(Vector Institute), Stephen A. Murray(Jackson Laboratory), Alexander Alanine(Roche (Switzerland)), Laurence Lovat(University College London), Steve Wood(University of Southampton), Glenys A. Tennent(The Royal Free Hospital), J. Ruth Gallimore(The Royal Free Hospital), Misao Suzuki(Kumamoto University), Roland Jakob‐Roetne(Roche (Switzerland)), Cornelia Hertel(Roche (Switzerland)), A. C. Purvis(University of Southampton), K Yamamura(Kumamoto University), John A. Kemp(Roche (Switzerland)), Tamás Bartfai(Translational Therapeutics (United States)), W. L. Hutchinson(The Royal Free Hospital), T. Hoffmann(Roche (Switzerland)), Simon Kolstoe(University of Portsmouth), J. Herbert(The Royal Free Hospital), Darren A. Thompson(University of Sussex)
Cited by 545
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k